Literature DB >> 21286838

Different black box warning labeling for same-class drugs.

Orestis A Panagiotou1, Despina G Contopoulos-Ioannidis, Panagiotis N Papanikolaou, Evangelia E Ntzani, John P A Ioannidis.   

Abstract

INTRODUCTION: Black box warnings (BBWs) are the strongest medication-related safety warnings in a drug's labeling information and highlight major risks. Absence of a BBW or asynchronous addition of a BBW among same-class drugs could have major implications.
METHODS: We identified the 20 top-selling drugs in 2008 (10 with BBWs and 10 without BBWs on their label) that belonged to different drug classes. We collected labeling information on all drugs belonging in these 20 classes, and recorded differences in the presence and timing of acquisition of BBWs for same-class drugs.
RESULTS: Across the 20 evaluated drug classes, we identified 176 different agents, of which 7 had been withdrawn for safety reasons. The reasons for the withdrawals became BBWs in other same-class agents only in two of the seven cases. Differences were identified in 9 of the 20 classes corresponding to 15 BBWs that were not present in all drugs of the same class. The information for 10 of the 15 different BBWs were included in the labels of same-class drugs as simple warnings or text, while it was absent entirely in 5 BBWs. The median interval from the time the BBW had appeared in another drug of the same class was 66 months. DISCUSSION: Differences in BBW labeling in same-class drugs are common and shape impressions about the safety of similar agents. BBW labeling needs to become more systematic.

Mesh:

Substances:

Year:  2011        PMID: 21286838      PMCID: PMC3101972          DOI: 10.1007/s11606-011-1633-9

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  32 in total

1.  Coverage of FDA medication boxed warnings in commonly used drug information resources.

Authors:  Christine M Cheng; B Joseph Guglielmo; Judy Maselli; Andrew D Auerbach
Journal:  Arch Intern Med       Date:  2010-05-10

2.  Boxed warnings and other FDA communication tools.

Authors:  Norman S Marks; Karen Weiss
Journal:  Am Fam Physician       Date:  2010-02-01       Impact factor: 3.292

Review 3.  Formulary decisions: then and now.

Authors:  Bradley A Boucher
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

Review 4.  The formulary process from a risk management perspective.

Authors:  Jack H Raber
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

5.  Risk management policy and black-box warnings: a qualitative analysis of US FDA proceedings.

Authors:  Daniel M Cook; Rama K Gurugubelli; Lisa A Bero
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

6.  Lost in transmission--FDA drug information that never reaches clinicians.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  N Engl J Med       Date:  2009-10-21       Impact factor: 91.245

Review 7.  Inside the black box: current policies and concerns with the United States Food and Drug Administration's highest drug safety warning system.

Authors:  Kylene Halloran; Paul G Barash
Journal:  Curr Opin Anaesthesiol       Date:  2010-06       Impact factor: 2.706

8.  Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention.

Authors:  Balthasar L Hug; Daniel J Witkowski; Colin M Sox; Carol A Keohane; Diane L Seger; Catherine Yoon; Michael E Matheny; David W Bates
Journal:  J Gen Intern Med       Date:  2009-11-06       Impact factor: 5.128

9.  Prescriber compliance with black box warnings in older adult patients.

Authors:  Judith R Ricci; Charmaine Coulen; Jan E Berger; Marsha C Moore; Angela McQueen; Saira A Jan
Journal:  Am J Manag Care       Date:  2009-11-01       Impact factor: 2.229

10.  Impact of FDA black box advisory on antipsychotic medication use.

Authors:  E Ray Dorsey; Atonu Rabbani; Sarah A Gallagher; Rena M Conti; G Caleb Alexander
Journal:  Arch Intern Med       Date:  2010-01-11
View more
  6 in total

1.  Drug vs class-specific black box warnings: does one bad drug spoil the bunch?

Authors:  Stacie B Dusetzina; G Caleb Alexander
Journal:  J Gen Intern Med       Date:  2011-06       Impact factor: 5.128

Review 2.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

3.  Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public data.

Authors:  Handong Ma; Chunhua Weng
Journal:  J Biomed Inform       Date:  2016-02-03       Impact factor: 6.317

4.  A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States.

Authors:  Yuko Hoshino; Mamoru Narukawa
Journal:  Ther Innov Regul Sci       Date:  2022-07-25       Impact factor: 1.337

Review 5.  Pharmacovigilance: reporting requirements throughout a product's lifecycle.

Authors:  Sylvia Lucas; Jessica Ailani; Timothy R Smith; Ahmad Abdrabboh; Fei Xue; Marco S Navetta
Journal:  Ther Adv Drug Saf       Date:  2022-09-27

6.  A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.

Authors:  Cynthia Richards; Dan V Iosifescu; Rajnish Mago; Elias Sarkis; James Reynolds; Brooke Geibel; Matthew Dauphin
Journal:  J Psychopharmacol       Date:  2017-08-31       Impact factor: 4.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.